Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma.
10.3803/EnM.2016.31.1.100
- Author:
Min Ji JEON
1
;
Won Gu KIM
;
Soyoung SIM
;
Seonhee LIM
;
Hyemi KWON
;
Tae Yong KIM
;
Young Kee SHONG
;
Won Bae KIM
Author Information
1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. wongukim@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Thyroid cancer, papillary;
Telomerase;
Mutation
- MeSH:
Cell Line;
Cohort Studies;
DNA;
Humans;
Polymerase Chain Reaction;
Prevalence*;
Recurrence;
Telomerase;
Thyroid Gland*;
Thyroid Neoplasms*
- From:Endocrinology and Metabolism
2016;31(1):100-104
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Transcriptional activating mutations of telomerase reverse transcriptase (TERT) are associated with more aggressive thyroid cancer. We evaluated the significance of TERT promoter mutations in Korean patients with classic papillary thyroid cancer (PTC). METHODS: Genomic DNA was isolated from four thyroid cancer cell lines and 35 fresh-frozen PTC tissues. TERT promoter mutations (C228T and C250T) and the BRAF V600E mutation were evaluated by polymerase chain reaction amplification and direct sequencing. RESULTS: The CC228229TT mutation in the TERT promoter was detected in BCPAP cells and the C250T mutation was found in 8505C cells. No TERT promoter mutation was observed in Cal-62 or ML-1 cells. The C228T mutation was found in only 1 of 35 (2.8%) PTCs and no C250T mutations were detected in any of the study subjects. The BRAF V600E mutation was found in 20 of 35 (57.1%) PTCs. One patient with the C228T TERT mutation also harbored the BRAF V600E mutation and developed a recurrence. CONCLUSION: The prevalence of somatic TERT promoter mutations was low in Korean patients with classic PTC. Therefore, the prognostic role of TERT promoter mutations might be limited in this patient cohort.
